CHRONIC MYELOID LEUKEMIA: EPIDEMIOLOGY AND FIFTEENTH YEARS OF THERAPY IN THE NOVOSIBIRSK REGION
Anna Sergeevna LYAMKINA1, Lyudmila Mikhaylovna MASLOVA2, Olesya Vladimirovna NAUMENKO3, Elena Vasilyevna MELNICHENKO2, Yuliya Nikolaevna OBGOLTS2, Anastasiya Borisovna LOGINOVA4, Elena Vyacheslavovna DARAGAN3, Irina Nikolaevna NECHUNAEVA2, Ekaterina Valerievna VORONTSOVA3, Lyubov Anatolievna SHPAGINA5, Anatoly Vasilyevic YUDANOV3, Konstantin Vasilyevich KHALZOV4, Tatyana Ivanovna POSPELOVA6
1Novosibirsk State Medical University of Minzdrav of Russia City Clinical Hospital № 2
anna_lyam@mail.ru
2City Clinical Hospital № 2
post_gem@mail.ru
3State Novosibirsk Regional Clinical Hospital
gnokb@oblmed.nsk.ru
4Novosibirsk State Medical University of Minzdrav of Russia
post_gem@mail.ru
5Novosibirsk State Medical University of Minzdrav of Russia, City Clinical Hospital № 2
info@gbuzgkb2.ru
6Novosibirsk State
Medical University of Minzdrav of Russia, City Clinical Hospital № 2,
State Novosibirsk Regional Clinical Hospital
post_gem@mail.ru
Keywords: хронический миелолейкоз, эпидемиология, полный цитогенетический ответ, большой молекулярный ответ, выживаемость
Abstract
The incidence of chronic
myeloid leukemia from 2004 to 2018 amounted to 0.63 per 100 000 people
per year. The prevalence of chronic myeloid leukemia over the past 15
years has increased from 1.88 to 7.02 case per 100 000 people. We have
analyzed the therapy outcomes of chronic myeloid leukemia of patients,
received imatinib treatment for more than 12 month (165 patients).
Complete hematologic response is attained in 88.5 % cases (146
patients), complete cytogenetic response (CCR) (ph+<0 %) - in 72.1 %
cases (119 patients), major molecular response (MMR) - in 50.3 % cases
(83 patients). The primary resistance to imatinib is observed in 21.8 %
cases (36 patients), secondary - in 6.1 % cases (10 patients - 7
patients have lost the complete hematologic response and CCR and 3
patients have lost the CCR and MMR). The thirteen patients of those, who
have primary or secondary resistance to imatinib have been treated with
second-generation tyrosine kinase inhibitors (nilotinib, dasatinib) and
in 93,3 % cases (14 patients) CCR have been obtained, 10 patients (66.7
%) have attained the CCR and 9 patients (60 %) have achieved MMR. Among
all those patients treated with I and II generations tyrosine kinase
inhibitors, we have carried out the overall survival (OS) analysis and
obtained following results: the median of OS have not been achieved,
5-year OS rate is estimated as 90 %, 10-year OS rate - more than 77 %,
calculated 15-year OS - more than 60 %.
|
